Raab & Moskowitz Asset Management LLC Vertex Pharmaceuticals Inc Transaction History

Raab & Moskowitz Asset Management LLC

$393 Million
Q3 2024

A detailed history of Raab & Moskowitz Asset Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Raab & Moskowitz Asset Management LLC holds 1,749 shares of VRTX stock, worth $713,906. This represents 0.21% of its overall portfolio holdings.

Number of Shares

1,749

Previous 1,786 2.07%

Holding current value

$713,906

Previous $837,000 2.87%

% of portfolio

0.21%

Previous 0.23%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$460.0 - $505.78 $17,020 - $18,713	-37 Reduced 2.07%	1,749 $813,000
Q2 2024 Aug 15, 2024	BUY	$392.81 - $485.53 $18,854 - $23,305	48 Added 2.76%	1,786 $837,000
Q4 2023 Feb 02, 2024	SELL	$343.0 - $410.68 $9,261 - $11,088	-27 Reduced 1.53%	1,738 $707,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $16,427 - $18,739	-58 Reduced 3.18%	1,765 $556,000
Q4 2022 Jan 27, 2023	BUY	$285.76 - $321.48 $35,720 - $40,185	125 Added 7.36%	1,823 $0
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $1,369 - $1,527	-5 Reduced 0.29%	1,698 $491,000
Q1 2022 May 10, 2022	BUY	$221.42 - $260.97 $11,071 - $13,048	50 Added 3.02%	1,703 $444,000
Q1 2021 Apr 28, 2021	BUY	$207.02 - $241.31 $3,105 - $3,619	15 Added 0.92%	1,653 $355,000
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $1,242 - $1,656	-6 Reduced 0.36%	1,638 $387,000
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $1,022 - $1,212	4 Added 0.24%	1,644 $447,000
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $6,313 - $8,282	-28 Reduced 1.68%	1,640 $476,000
Q1 2018 Apr 25, 2018	BUY	$151.6 - $177.13 $252,868 - $295,452	1,668 New	1,668 $271,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raab & Moskowitz Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Raab & Moskowitz Asset Management LLC with notifications on news.

Account

Raab & Moskowitz Asset Management LLC Vertex Pharmaceuticals Inc Transaction History